Skip to main content
. Author manuscript; available in PMC: 2013 Mar 15.
Published in final edited form as: Int J Radiat Oncol Biol Phys. 2011 Jul 19;82(4):1367–1375. doi: 10.1016/j.ijrobp.2011.05.027

Table 3.

Summary of Worst Adverse Event Definitely, Probably, or Possibly Related to Treatment Per Patient Occurring Prior to Surgery

Adverse Event Grade Capecitabine/Ir
inotecan/RT
(n=52)
Capecitabine/O
xaliplatin/RT
(n=52)
Worst non-hematologic 1 15 (29%) 11 (21%)
2 23 (44%) 27 (52%)
3 11 (21%) 12 (23%)
4 0 (0%) 2 (4%)
5 0 (0%) 0 (0%)
Worst overall 1 12 (23%) 9 (17%)
2 25 (48%) 29 (56%)
3 14 (27%) 12 (23%)
4 0 (0%) 2 (4%)
5 0 (0%) 0 (0%)

Adverse events were graded with CTCAE version 3.0.